Lumos Pharma, Inc. (NASDAQ:LUMO) Position Lessened by Private Advisor Group LLC

Private Advisor Group LLC lowered its stake in shares of Lumos Pharma, Inc. (NASDAQ:LUMO – Get Rating) by 37.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,013 shares of the company’s stock after selling 10,000 shares during the quarter. Private Advisor Group LLC owned approximately 0.20% of Lumos Pharma worth $151,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Urban Wealth Management LLC bought a new position in Lumos Pharma in the 2nd quarter valued at about $27,000. Key Financial Inc acquired a new position in shares of Lumos Pharma during the second quarter valued at approximately $84,000. Finally, Opaleye Management Inc. acquired a new position in shares of Lumos Pharma during the second quarter valued at approximately $166,000. 30.53% of the stock is currently owned by institutional investors.

Lumos Pharma Trading Up 4.5 %

NASDAQ LUMO opened at $3.94 on Friday. Lumos Pharma, Inc. has a 1 year low of $2.95 and a 1 year high of $10.27. The stock’s 50-day moving average price is $5.17 and its two-hundred day moving average price is $7.27. The company has a market cap of $33.10 million, a PE ratio of -1.16 and a beta of 1.03.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on LUMO shares. Jefferies Financial Group lowered Lumos Pharma from a “buy” rating to a “hold” rating in a research note on Thursday, December 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Lumos Pharma in a research report on Tuesday, November 15th. Finally, Oppenheimer dropped their target price on shares of Lumos Pharma to $18.00 in a report on Thursday, November 17th.

Lumos Pharma Profile

(Get Rating)

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders.